ERBB2 and neoplasm: In the subsequent anti-tumor therapy (Table 2), there were higher rates of anti-HER2 monoclonal antibodies (27.3% versus 14.0%) and ADCs in the LC group (20.0% versus 1.4%), while tyrosine kinase inhibitors (TKIs) use was more common in the ARX788 group (38.0% versus 26.8%).